Last Updated: 12 Nov 2024
Executive Summary
Smith & Nephew SNATS Inc. (SNN) is a global medical device company with a market capitalization of $10.59 billion. The company's strong financial performance, including a 0.244% quarterly earnings growth YOY and a 0.034% quarterly revenue growth YOY, has led to analyst recommendations of "Strong Buy" and a target price of $32.5. The company's technical analysis indicates a bullish trend, with the stock price trading above its 50-day and 200-day moving averages.
Company Overview
Smith & Nephew develops, manufactures, markets, and sells medical devices worldwide. The company's products include orthopedic implants, wound care products, and sports medicine devices. Smith & Nephew is headquartered in Watford, the United Kingdom.
Fundamental Analysis
Smith & Nephew's fundamental analysis shows strong financial performance. The company has an EBITDA of $1.076 billion, a PERatio of 34.7, and a PEGRatio of 0.403. The company's profit margin is 0.0541, and its operating margin TTM is 0.116. Smith & Nephew's return on assets TTM is 0.0451, and its return on equity TTM is 0.0584.
Technical Analysis
Smith & Nephew's technical analysis indicates a bullish trend. The stock price is trading above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is 62.77, which indicates that the stock is overbought but still has room to run.
Short Term Outlook
Smith & Nephew's short-term outlook is positive. The company's strong financial performance and bullish technical analysis suggest that the stock price will continue to rise in the short term. The stock is expected to reach its analyst target price of $32.5 by the end of the year.
Long Term Outlook
Smith & Nephew's long-term outlook is also positive. The company's strong fundamentals and growing market share suggest that the stock price will continue to rise in the long term. The company is expected to benefit from the increasing demand for medical devices due to the aging population and the rising incidence of chronic diseases.
Analyst Recommendations
Analysts have a "Strong Buy" recommendation on Smith & Nephew. The company's strong financial performance, bullish technical analysis, and positive long-term outlook make it a good investment opportunity.
